Interestingly, suppression of TDP-43 aggregation was not observed in response to other reported HSF1 modulating compounds including the Hsp90 inhibitor 17-AAG and the current FDA-approved ALS drug riluzole (Supplementary Fig. 10)58. This evidence concerns the gene HSF1 and amyotrophic lateral sclerosis.